首页> 美国卫生研究院文献>Molecules >Design Synthesis and Biological Evaluation of Hydroxamic Acid Derivatives as Potential High Density Lipoprotein (HDL) Receptor CLA-1 Up-Regulating Agents
【2h】

Design Synthesis and Biological Evaluation of Hydroxamic Acid Derivatives as Potential High Density Lipoprotein (HDL) Receptor CLA-1 Up-Regulating Agents

机译:潜在的高密度脂蛋白(HDL)受体CLA-1上调剂异羟肟酸衍生物的设计合成和生物学评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) were reported in our recent publication as novel human high density lipoprotein (HDL) receptor CD36 and Lysosomal integral membrane protein-II Analogous-1 (CLA-1) up-regulators. As part of a broader effort to more fully explore the structure-activity relationships (SAR) of CLA-1 up-regulators, we synthesized a series of hydroxamic acid derivatives and evaluated their CLA-1 up-regulating activities in HepG2 cells. Some compounds exhibited over 10-fold up-regulation of CLA-1 expression in HepG2 cells at 10 μg/mL concentration. The compound >1g showed the best potency, with a lower EC50 than TSA (EC50 = 0.32 μM versus 1.2 μM). These compounds provide early new CLA-1 up-regulators with potential for treating atherosclerosis.
机译:Trichostatin A(TSA)和Suberoylanilide异羟肟酸(SAHA)在我们最近的出版物中被报道为新型人类高密度脂蛋白(HDL)受体CD36和溶酶体整合膜蛋白II类似物1(CLA-1)上调剂。为了更全面地探索CLA-1上调剂的结构-活性关系(SAR),我们进行了广泛的努力,我们合成了一系列异羟肟酸衍生物,并评估了它们在HepG2细胞中的CLA-1上调活性。在10μg/ mL浓度下,某些化合物在HepG2细胞中的CLA-1表达上调了10倍以上。化合物> 1g 显示出最好的效力,其EC50低于TSA(EC50 = 0.32μM对1.2μM)。这些化合物为早期的新型CLA-1上调剂提供了治疗动脉粥样硬化的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号